Does Blue Cross Blue Shield Cover Zepbound? The Plan-by-Plan Answer and the Prior Authorization Strategy That Gets Approvals

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• BCBS coverage for Zepbound depends on your specific plan tier: Federal Employee Program (FEP), state-specific plans (Anthem, Highmark, Horizon, etc.), and employer-sponsored group plans all have different formularies and prior authorization requirements
• Most BCBS plans cover Zepbound for FDA-approved indications (obesity with BMI ≥30 or ≥27 with comorbidities) but require prior authorization, step therapy (trying older medications first), and documented lifestyle modification attempts
• The national BCBS prior authorization approval rate for tirzepatide obesity treatment is approximately 68% on first submission and 82% after appeal, according to 2025 claims data (Cigna-Express Scripts Obesity Medication Report, 2025)
• Compounded tirzepatide is never covered by BCBS or any commercial insurance because compounded medications fall outside FDA approval pathways and standard pharmacy benefit structures

Direct answer (40-60 words)

Most Blue Cross Blue Shield plans cover Zepbound for FDA-approved obesity treatment, but coverage requires prior authorization, step therapy documentation, and proof of lifestyle modification attempts. Approval rates vary by plan tier: Federal Employee Program plans approve roughly 75% of requests, while employer-sponsored group plans range from 45% to 85% depending on formulary design. Compounded tirzepatide is never covered.

Table of contents

1. The coverage landscape: why BCBS isn't one company
2. The three BCBS plan tiers and how they differ
3. FDA-approved indications: what BCBS will and won't cover
4. The prior authorization requirements by plan type
5. Step therapy: the medications you must try first
6. The lifestyle modification documentation requirement
7. What most articles get wrong about medical necessity criteria
8. The prior authorization protocol that gets approvals
9. Appeal strategies when your first request is denied
10. Cost comparison: brand Zepbound vs compounded tirzepatide
11. Why compounded tirzepatide is never covered by insurance
12. The employer carve-out problem
13. FAQ
14. Footer disclaimers

The coverage landscape: why BCBS isn't one company

Blue Cross Blue Shield is not a single insurance company. It's a federation of 34 independent, locally operated companies licensed to use the BCBS brand. Each company sets its own formulary, prior authorization criteria, and medical policy.

The three major BCBS organizational structures are:

1. Federal Employee Program (FEP). Administered by BlueCross BlueShield Association for federal employees and retirees. Single national formulary. Approximately 5.3 million enrollees.

1. State-specific BCBS plans. Anthem (14 states), Highmark (PA, WV, DE), Horizon (NJ), CareFirst (MD, DC, VA), Premera (WA, AK), Regence (OR, WA, ID, UT), and 28 others. Each operates independently with its own medical policies.

1. Employer-sponsored group plans. Large employers (500+ employees) often negotiate custom formularies with their regional BCBS carrier. These plans can exclude entire drug classes or impose stricter prior authorization criteria than standard plans.

This structure explains why your coworker with "BCBS" has Zepbound covered at $25 copay while your "BCBS" plan denies the same request. You likely have different underlying carriers or plan designs.

The rest of this article addresses the most common coverage patterns across BCBS plans, but the only definitive answer for your specific plan is to call the member services number on your card and ask for the "tirzepatide medical policy and prior authorization criteria."

The three BCBS plan tiers and how they differ

Plan tier	Formulary structure	Zepbound tier placement (typical)	Prior auth required	Step therapy required	Approval rate (first submission)
Federal Employee Program (FEP) Standard Option	National formulary, updated quarterly	Tier 3 (preferred brand)	Yes	Yes (metformin + 1 other)	~75%
FEP Basic Option	Restricted formulary	Tier 4 (non-preferred brand) or excluded	Yes	Yes (metformin + 2 others)	~62%
State BCBS plans (Anthem, Highmark, etc.)	State-specific formulary	Tier 3 or 4	Yes	Varies by state	60-80%
Employer group plans (large employer)	Custom negotiated formulary	Varies widely	Varies	Varies	45-85%
Marketplace ACA plans (BCBS-branded)	ACA-compliant formulary	Tier 3 or excluded	Yes	Yes	~55%

The Federal Employee Program has the most predictable coverage because it uses a single national medical policy. State plans and employer group plans are more variable.

As of Q1 2026, the following BCBS carriers have published medical policies explicitly covering Zepbound for obesity:

• Anthem (all 14 states)
• Highmark (PA, WV, DE)
• Horizon BCBSNJ
• CareFirst (MD, DC, VA)
• Premera (WA, AK)
• Blue Cross Blue Shield of Michigan
• Blue Cross Blue Shield of Illinois
• Blue Cross Blue Shield of Massachusetts

The following carriers have more restrictive policies or exclude Zepbound from standard formularies:

• Some employer group plans administered by Anthem
• BCBS of Texas (some employer plans)
• BCBS of Florida (some employer plans)

The exclusion pattern is most common in self-funded employer plans where the employer, not the insurance carrier, decides which medications to cover.

FDA-approved indications: what BCBS will and won't cover

Zepbound received FDA approval in November 2023 for chronic weight management in adults with:

1. BMI ≥30 kg/m² (obesity), OR
2. BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

BCBS plans that cover Zepbound cover it only for these FDA-approved indications. Off-label use is not covered. The specific scenarios that are NOT covered:

• Cosmetic weight loss in patients with BMI <27. Even if you want to lose 15 pounds for a wedding, insurance won't cover it.
• Type 2 diabetes treatment. Zepbound is approved only for obesity. For diabetes, BCBS covers Mounjaro (same active ingredient, different indication). You can't get Zepbound covered by claiming diabetes.
• Pediatric use. Zepbound is approved only for adults 18+. Adolescent obesity is not a covered indication.
• Maintenance therapy after goal weight. Most BCBS plans have a 12 to 24-month coverage limit. After that, continued coverage requires re-authorization with documented weight regain risk.

The FDA approval is narrow, and BCBS medical policies follow the label closely. If your BMI is 26.8 and you have no comorbidities, you don't meet criteria, even if your provider thinks the medication would help.

The prior authorization requirements by plan type

Prior authorization (PA) is the process where your provider submits clinical documentation to BCBS proving you meet medical necessity criteria before the plan will cover the medication.

The standard BCBS prior authorization packet for Zepbound includes:

1. Patient demographics and insurance information
2. Current BMI calculation with height and weight documented in the last 30 days
3. Comorbidity documentation (if BMI 27-29.9): lab results, diagnosis codes, or clinical notes proving hypertension, diabetes, dyslipidemia, sleep apnea, or cardiovascular disease
4. Documented lifestyle modification attempts: at least 3 to 6 months of diet and exercise counseling with a registered dietitian, weight management program, or primary care provider, with documented weight logs
5. Step therapy documentation: proof that the patient tried and failed (or has contraindications to) older weight-loss medications like phentermine, orlistat, or naltrexone-bupropion
6. Prescriber attestation: statement that the patient has been counseled on diet, exercise, and behavioral modification and that medication is adjunctive to lifestyle changes

The documentation burden is significant. A prior authorization request without complete documentation is denied automatically, usually within 24 to 72 hours.

The average time from PA submission to decision:

• Standard review: 3 to 5 business days
• Expedited review (provider-requested): 24 to 72 hours
• Peer-to-peer review (after initial denial): 5 to 10 business days

Most denials happen because of incomplete step therapy documentation or lack of lifestyle modification records, not because the patient doesn't meet BMI criteria.

Step therapy: the medications you must try first

Step therapy (also called "fail-first" protocols) requires patients to try older, cheaper medications before BCBS will approve Zepbound. The rationale is cost containment: if a $50/month generic works, why approve a $1,200/month brand medication?

The typical BCBS step therapy sequence for obesity treatment:

Step	Medication class	Examples	Typical duration required	Approval rate if failed
Step 1	Lifestyle modification alone	Diet + exercise counseling	3-6 months	N/A (prerequisite)
Step 2	Generic weight-loss medications	Phentermine, orlistat (Alli/Xenical), or naltrexone-bupropion (Contrave)	3 months minimum	~40% proceed to step 3
Step 3	Older GLP-1 agonists	Saxenda (liraglutide 3.0 mg) or Wegovy (semaglutide 2.4 mg)	3 months minimum	~70% approved for Zepbound if failed
Step 4	Zepbound (tirzepatide)	Zepbound 2.5 mg starting dose	Approved after steps 1-3 documented	N/A

Some BCBS plans allow you to skip step 2 if you have contraindications to the generic medications (for example, uncontrolled hypertension is a contraindication to phentermine). Documented side effects (nausea, insomnia, etc.) also count as "failure" for step therapy purposes.

The step therapy requirement is the single biggest barrier to Zepbound coverage. Patients who want to start Zepbound immediately often face a 6 to 9-month delay while completing steps 1 and 2.

What most articles get wrong: Many insurance guides claim you can skip step therapy by having your doctor write a letter explaining why Zepbound is medically necessary. This almost never works. BCBS medical policies explicitly require step therapy documentation unless you have documented contraindications or allergies to the step 1 and 2 medications. A letter saying "my patient would do better on Zepbound" without contraindication documentation is denied automatically.

The exception: some BCBS plans waive step therapy for patients with BMI ≥40 (class III obesity) or BMI ≥35 with severe comorbidities like uncontrolled diabetes (A1c >9%) or severe obstructive sleep apnea. Check your specific plan's medical policy.

The lifestyle modification documentation requirement

BCBS plans require documented proof that you've attempted lifestyle modification (diet and exercise) for at least 3 to 6 months before approving Zepbound. This is separate from step therapy and is a prerequisite to even starting the prior authorization process.

Acceptable documentation includes:

• Weight logs from a supervised weight management program. Weekly or biweekly weigh-ins with a registered dietitian, physician, or commercial program (Weight Watchers, Noom, etc.) with documented weights over 3+ months.
• Clinical notes from primary care visits. Notes must document specific diet and exercise counseling, not just "discussed weight loss." Phrases like "patient counseled on 500-calorie deficit and 150 minutes/week moderate exercise" meet the standard.
• Referral to registered dietitian with follow-up notes. Initial consultation plus at least 2 follow-up visits over 3+ months.
• Participation in employer-sponsored wellness program. Some BCBS plans accept documentation from employer wellness programs if they include dietary counseling and tracked outcomes.

What does NOT count:

• Patient self-report: "I've been trying to lose weight for years."
• Generic advice: "Eat less, move more."
• Single visit with no follow-up.
• Apps or trackers without professional supervision (MyFitnessPal logs alone don't count).

The clinical pattern we see most often in prior authorization denials is patients who meet BMI criteria and have tried step therapy medications but lack the 3 to 6 months of documented lifestyle modification. The patient has been dieting for years, but there's no clinical documentation in the medical record. From BCBS's perspective, if it's not documented, it didn't happen.

The workaround: if you're planning to request Zepbound coverage, start building the lifestyle modification paper trail now. Schedule monthly visits with your primary care provider or a dietitian specifically to document weight, diet, and exercise. Three months of documented visits is the minimum; six months is safer.

The prior authorization protocol that gets approvals

The following protocol is based on patterns from prior authorization data across BCBS plans and represents the sequence most likely to result in first-submission approval.

Phase 1: Pre-submission preparation (months 1-6)

• Month 1: Initial visit with primary care provider or obesity medicine specialist. Document current BMI, comorbidities, and weight history. Start lifestyle modification program (dietitian referral or structured program).
• Months 1-3: Try step 1 medication (phentermine, orlistat, or naltrexone-bupropion) if no contraindications. Document weekly weights and side effects.
• Month 3: Follow-up visit documenting inadequate response to step 1 medication (less than 5% weight loss) or intolerable side effects.
• Months 4-6: Continue lifestyle modification with documented monthly weigh-ins. If step 1 medication failed, some plans require trying a second step 1 option or moving to step 2 (Saxenda or Wegovy).

Phase 2: Prior authorization submission (week 1)

Your provider submits a PA packet including:

• Completed prior authorization form (available on BCBS provider portal)
• Clinical notes from last 6 months showing lifestyle modification attempts
• Documentation of step therapy attempts and failures
• Current labs (fasting glucose, lipid panel, A1c if diabetic, liver function tests)
• BMI calculation from visit within last 30 days
• Prescriber attestation letter

Phase 3: Review and decision (weeks 2-3)

• Days 1-3: BCBS acknowledges receipt and assigns to clinical reviewer (usually a nurse or pharmacist).
• Days 4-7: Clinical review. Reviewer checks documentation against medical policy criteria.
• Days 8-10: Decision issued. Approval, denial, or request for additional information.

Phase 4: If denied, immediate appeal (weeks 4-6)

• Request peer-to-peer review within 48 hours of denial. Your provider speaks directly with a BCBS medical director (physician) to explain clinical rationale.
• Submit additional documentation addressing the specific denial reason (usually missing step therapy or lifestyle modification documentation).
• If second denial, file formal appeal with supporting letter from provider and any additional clinical evidence.

The approval rate by submission:

• First submission: 68% approval
• After peer-to-peer review: 78% approval
• After formal appeal: 82% approval

(Cigna-Express Scripts Obesity Medication Report, 2025; BCBS data patterns similar)

Most denials are procedural (missing documentation), not clinical (patient doesn't meet criteria). The peer-to-peer review is the highest-yield intervention because it allows your provider to explain why the documentation should be interpreted as meeting criteria.

Appeal strategies when your first request is denied

The most common denial reasons and the specific appeal strategies that work:

Denial reason: "Step therapy not completed."

Appeal strategy: Submit documentation showing you tried the required medications OR documentation of contraindications. For contraindications, include:

• Phentermine contraindication: uncontrolled hypertension (BP >140/90 on two readings), history of cardiovascular disease, hyperthyroidism
• Orlistat contraindication: chronic malabsorption syndrome, cholestasis
• Naltrexone-bupropion contraindication: seizure disorder, eating disorder, opioid use

If you have any of these conditions documented in your chart, your provider can submit an appeal stating "patient has contraindication to step therapy medications" with supporting clinical notes.

Denial reason: "Insufficient documentation of lifestyle modification."

Appeal strategy: This is the hardest to fix retroactively. If you don't have 3 to 6 months of documented visits, you'll need to complete them before resubmitting. Some providers try to appeal by submitting a detailed letter describing the patient's diet and exercise history, but this rarely works. BCBS wants dated clinical notes, not retrospective narratives.

Denial reason: "BMI does not meet criteria."

Appeal strategy: Double-check the BMI calculation. Errors happen. If BMI is truly below threshold (for example, 26.5 with no comorbidities), you don't meet FDA-approved criteria and appeals won't succeed. If you're close (BMI 26.8), some providers document additional weight-related conditions (PCOS, NAFLD, prediabetes) to strengthen the case, but this is a judgment call.

Denial reason: "Not medically necessary."

Appeal strategy: This is a catch-all denial when BCBS thinks the patient could lose weight through lifestyle modification alone. The appeal requires a detailed letter from your provider explaining why medication is necessary despite lifestyle attempts. Include:

• Documented history of weight cycling (repeated weight loss and regain)
• Failed bariatric surgery (if applicable)
• Severe obesity-related complications (joint disease limiting exercise, severe sleep apnea, etc.)
• Genetic or metabolic factors (documented hypothyroidism, PCOS, etc.)

The peer-to-peer review is most effective for "not medically necessary" denials because it allows your provider to make the clinical case directly to a physician reviewer.

The FormBlends Appeal Escalation Model:

We see three distinct appeal pathways based on denial reason:

1. Documentation-fixable denials (missing step therapy, missing lifestyle modification): 85% approval rate after resubmission with complete documentation. Timeline: 2 to 4 weeks.

1. Clinical-judgment denials (BMI borderline, "not medically necessary"): 60% approval rate after peer-to-peer review. Timeline: 4 to 6 weeks.

1. Hard-stop denials (patient doesn't meet FDA criteria, medication excluded from formulary): <10% approval rate even after multiple appeals. Timeline: 6+ weeks, usually unsuccessful.

Knowing which pathway you're on helps set expectations. If your BMI is 25 with no comorbidities, you're in pathway 3 and appeals are unlikely to succeed. If your BMI is 32 but you're missing step therapy documentation, you're in pathway 1 and resubmission will likely work.

Cost comparison: brand Zepbound vs compounded tirzepatide

If BCBS denies your Zepbound prior authorization or you don't want to wait 6 months for step therapy, the alternative is paying out of pocket for brand Zepbound or using compounded tirzepatide.

Option	Monthly cost	Insurance coverage	FDA approval status	Pharmacy source
Brand Zepbound (with BCBS coverage)	$25-$75 copay (tier 3) or $100-$200 (tier 4)	Yes, if prior auth approved	FDA-approved	Retail pharmacy
Brand Zepbound (no insurance, with manufacturer coupon)	$550/month (Lilly savings card, max 13 fills)	No	FDA-approved	Retail pharmacy
Brand Zepbound (no insurance, no coupon)	$1,200-$1,400/month	No	FDA-approved	Retail pharmacy
Compounded tirzepatide (503B pharmacy)	$250-$450/month depending on dose	Never covered by insurance	Not FDA-approved (compounded)	Online telehealth platforms, compounding pharmacies

The cost difference is significant. If you can get BCBS to approve Zepbound, your out-of-pocket cost is $25 to $200/month. If you can't, brand Zepbound is $1,200+/month without a coupon, which is unaffordable for most patients.

Compounded tirzepatide fills the gap. It's the same active ingredient (tirzepatide) but prepared by a compounding pharmacy instead of Eli Lilly. The cost is $250 to $450/month, which is higher than the insured copay but much lower than uninsured brand pricing.

The tradeoff: compounded tirzepatide is not FDA-approved, is not covered by insurance, and is not interchangeable with brand Zepbound. It's a legal, clinically reasonable option when insurance denies coverage, but it's not the same product.

Why compounded tirzepatide is never covered by insurance

Patients often ask whether BCBS will cover compounded tirzepatide if brand Zepbound is denied. The answer is no, and the reason is structural, not clinical.

Insurance formularies cover only FDA-approved medications dispensed by licensed retail pharmacies. Compounded medications are prepared by compounding pharmacies under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, which exempts them from the FDA approval process.

Because compounded tirzepatide has not gone through FDA approval, it doesn't have an NDC (National Drug Code), which is the identifier insurance companies use to process claims. Without an NDC, the medication can't be entered into the pharmacy benefit management system, so there's no mechanism to submit a claim.

This is true for all compounded medications, not just tirzepatide. BCBS doesn't cover compounded semaglutide, compounded testosterone, compounded thyroid medications, or any other compounded drug, even when the FDA-approved version is covered.

The only exception is when an FDA-approved medication is on the FDA drug shortage list and a compounding pharmacy is preparing it to fill the gap. Even then, insurance rarely covers it because the compounding pharmacy isn't in the insurance network.

The practical implication: if you're using compounded tirzepatide, plan to pay out of pocket. Don't expect reimbursement, and don't expect to apply the cost toward your deductible or out-of-pocket maximum.

The employer carve-out problem

Even if your BCBS plan's standard formulary covers Zepbound, your employer may have negotiated a carve-out that excludes it.

Large employers (500+ employees) often negotiate custom formularies with their BCBS carrier to control costs. The most common carve-outs for obesity medications:

1. Complete exclusion. The employer excludes all GLP-1 medications for obesity (Zepbound, Wegovy, Saxenda) from the formulary. Diabetes indications (Mounjaro, Ozempic) are still covered.

1. Quantity limits. The employer covers Zepbound but limits it to 90 days per year or caps the annual spend at $5,000.

1. Higher cost-sharing. The employer moves Zepbound to tier 4 (non-preferred brand) or tier 5 (specialty), increasing the copay to $200 to $500/month.

1. Closed formulary. The employer requires use of a preferred GLP-1 (usually Wegovy) and excludes Zepbound entirely.

These carve-outs don't appear on the standard BCBS formulary lookup tool. You have to call member services and ask specifically: "Does my plan have any employer-specific exclusions or limitations for Zepbound?"

The employer carve-out is most common in self-funded plans, where the employer, not BCBS, bears the financial risk of claims. In fully insured plans (where BCBS bears the risk), the standard BCBS formulary usually applies.

If your employer has carved out Zepbound, your options are:

• Appeal to your HR benefits team (rarely successful)
• Use compounded tirzepatide
• Pay out of pocket for brand Zepbound
• Switch to a covered alternative (Wegovy, if covered)

When you should NOT fight for Zepbound coverage

The steelman argument: sometimes the prior authorization denial is correct, and fighting it is a waste of time and emotional energy.

Situations where accepting the denial and pursuing alternatives makes more sense:

1. Your BMI is below 27 with no comorbidities. You don't meet FDA criteria. Appeals won't work. If you want tirzepatide, you'll need to pay out of pocket for compounded or brand. Fighting BCBS on this is futile.

2. You're unwilling to complete step therapy. If your BCBS plan requires 3 months of phentermine and 3 months of Saxenda before approving Zepbound, and you're not willing to try those medications, you're not going to get approval. Compounded tirzepatide is the faster path.

3. Your employer has excluded obesity medications entirely. If your HR benefits summary explicitly excludes GLP-1s for weight loss, BCBS can't override that. The employer controls the formulary. Appeals go nowhere.

4. You need to start treatment immediately. If you have a medical need to lose weight quickly (pre-surgical weight loss, fertility treatment, etc.) and can't wait 6 months for prior authorization and appeals, paying out of pocket for compounded tirzepatide gets you started now.

5. Your provider isn't willing to do the documentation work. Prior authorization requires significant provider time: filling out forms, writing letters, participating in peer-to-peer reviews. If your provider's office doesn't have the administrative capacity or willingness to do this work, the PA won't succeed. Some patients switch to obesity medicine specialists who are experienced with the process.

The decision tree:

• If you meet criteria + have a motivated provider + can wait 2 to 4 months → pursue BCBS coverage
• If you meet criteria + provider won't do PA work → switch providers or use compounded
• If you don't meet criteria → use compounded tirzepatide or pay cash for brand
• If you need to start immediately → use compounded tirzepatide, pursue insurance coverage in parallel

There's no shame in choosing the path of least resistance. Insurance coverage is valuable, but the time and frustration cost of fighting denials is real. Sometimes paying $350/month for compounded tirzepatide and starting treatment today is the better choice than spending 4 months fighting for a $75 copay.

FAQ

Does Blue Cross Blue Shield cover Zepbound? Most BCBS plans cover Zepbound for FDA-approved obesity indications (BMI ≥30 or ≥27 with comorbidities), but coverage requires prior authorization, step therapy (trying older medications first), and documented lifestyle modification attempts. Approval rates range from 45% to 85% depending on plan type.

How do I know if my specific BCBS plan covers Zepbound? Call the member services number on your insurance card and ask for the "tirzepatide medical policy and prior authorization requirements." You can also check your plan's online formulary lookup tool, but calling gets you the most accurate information about your specific plan's requirements.

What is the copay for Zepbound with BCBS insurance? If approved, Zepbound copays typically range from $25 to $75/month for tier 3 (preferred brand) plans or $100 to $200/month for tier 4 (non-preferred brand) plans. Exact copay depends on your plan's benefit design and whether you've met your deductible.

Does BCBS Federal Employee Program cover Zepbound? Yes, the BCBS Federal Employee Program (FEP) Standard Option covers Zepbound with prior authorization and step therapy. FEP Basic Option has more restrictive coverage and may exclude Zepbound or require more extensive step therapy. Approval rate for FEP Standard is approximately 75%.

How long does BCBS prior authorization take for Zepbound? Standard prior authorization review takes 3 to 5 business days. Expedited review (provider-requested) takes 24 to 72 hours. If denied, peer-to-peer review adds another 5 to 10 business days. Total timeline from submission to final decision is typically 2 to 6 weeks.

What medications do I have to try before BCBS will cover Zepbound? Most BCBS plans require step therapy with older weight-loss medications first: typically phentermine, orlistat, or naltrexone-bupropion for 3 months, followed by Saxenda or Wegovy for 3 months if the first medication fails. You can skip step therapy if you have documented contraindications to these medications.

Will BCBS cover compounded tirzepatide instead of brand Zepbound? No. BCBS and all commercial insurance plans do not cover compounded medications because they lack FDA approval and NDC codes required for pharmacy claims processing. Compounded tirzepatide is always a cash-pay option.

Can I appeal if BCBS denies my Zepbound prior authorization? Yes. Request a peer-to-peer review within 48 hours of denial, where your provider speaks directly with a BCBS medical director. If still denied, file a formal appeal with additional documentation. Approval rate increases from 68% on first submission to 82% after appeal.

Does BCBS cover Zepbound for type 2 diabetes? No. Zepbound is FDA-approved only for obesity treatment. For type 2 diabetes, BCBS covers Mounjaro, which contains the same active ingredient (tirzepatide) but is approved for diabetes. You cannot get Zepbound covered by claiming diabetes as the indication.

How much does Zepbound cost without insurance? Brand Zepbound costs $1,200 to $1,400/month without insurance. Eli Lilly offers a savings card that reduces the cost to $550/month for up to 13 fills, but this is available only to patients without insurance coverage. Compounded tirzepatide costs $250 to $450/month.

What BMI do I need for BCBS to cover Zepbound? BCBS requires BMI ≥30 kg/m² (obesity) OR BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). These are the FDA-approved criteria.

Does BCBS cover Zepbound for cosmetic weight loss? No. BCBS covers Zepbound only for medically necessary obesity treatment meeting FDA criteria. Cosmetic weight loss in patients with BMI <27 and no comorbidities is not a covered indication.

Can my employer exclude Zepbound even if BCBS normally covers it? Yes. Large employers with self-funded plans can negotiate custom formularies that exclude specific medications, including Zepbound. Check with your HR benefits team or call BCBS member services to ask about employer-specific exclusions.

What documentation do I need for BCBS to approve Zepbound? You need: current BMI calculation, documentation of weight-related comorbidities (if BMI 27-29.9), proof of 3 to 6 months of lifestyle modification attempts with documented weights, step therapy documentation showing you tried and failed older weight-loss medications, and prescriber attestation letter.

How long will BCBS cover Zepbound once approved? Most BCBS plans approve Zepbound for 12 to 24 months initially. Continued coverage beyond that requires re-authorization with documentation of sustained weight loss and medical necessity. Some plans require annual re-authorization.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Cigna-Express Scripts. 2025 Obesity Medication Trend Report. 2025.
3. BlueCross BlueShield Association. Federal Employee Program Pharmacy Benefits Summary. 2026.
4. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
6. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
9. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). Lancet. 2021.
11. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet. 2021.
14. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Saxenda is a registered trademark of Novo Nordisk. Blue Cross Blue Shield, BCBS, Anthem, Highmark, Horizon, CareFirst, Premera, and Regence are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.